Thinking Small: Small Molecules as Potential Synergistic Adjuncts to Checkpoint Inhibition in Melanoma
Metastatic melanoma remains the deadliest form of skin cancer. Immune checkpoint inhibition (ICI) immunotherapy has defined a new age in melanoma treatment, but responses remain inconsistent and some patients develop treatment resistance. The myriad of newly developed small molecular (SM) inhibitors...
Main Authors: | Alexander C. Chacon, Alexa D. Melucci, Shuyang S. Qin, Peter A. Prieto |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-03-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/22/6/3228 |
Similar Items
-
Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
by: Teresa Kim, et al.
Published: (2014-12-01) -
Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
by: Devayani Machiraju, et al.
Published: (2021-01-01) -
No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
by: Michele Guida, et al.
Published: (2021-01-01) -
Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
by: Magdalena Olbryt, et al.
Published: (2020-06-01) -
Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
by: Vera Petrova, et al.
Published: (2020-03-01)